Aether Therapeutics Company Research Report

Company Overview

• Name: Aether Therapeutics

• Mission: Aether Therapeutics is focused on curing diseases associated with the opioid epidemic and developing better therapies for pain. The company aims to cure and prevent Neonatal Abstinence Syndrome (NAS) and to provide effective withdrawal and weaning procedures.

• Founded: No information is available.

• Founders: Wolfgang Sadee and Rick Hawkins

• Key People:

• Wolfgang Sadee, Chief Science Officer & Founder

• Aaron Schuchart, President & Chief Executive Officer

• Rick Hawkins, Founder

• Jon Saxe, Chairman

• John McKew, Chief Clinical Advisor

• Headquarters: Austin, Texas

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Aether is known for developing a first-in-class preventive treatment for Neonatal Abstinence Syndrome.

Products

LD-6ßN (6 Beta Naltrexol)

• Product Description: LD-6ßN is a low-dose treatment strategy aimed at preventing addiction while maintaining analgesia and avoiding withdrawal symptoms. It is designed specifically for Neonatal Abstinence Syndrome during pregnancy.

• Key Features:

• Targets central opioid receptor sites by slow penetration and long retention.

• Acts as a dependence modulator to prevent opioid dependence.

• First-in-class treatment targeting Neonatal Abstinence Syndrome during pregnancy, working alongside existing opioid maintenance therapies.

Recent Developments

Publications and Research

• Breakthrough Papers (Feb 2, 2021):

• New model for Modulation of Opioid Dependence focusing on improving pain therapy and opioid use management.

• Validation of ultra-low-dose administration of 6BN as effective in treating neonatal opioid withdrawal.

• Pharmacological prevention of Neonatal Opioid Withdrawal.

Grants and Collaboration

• SBIR Fast-Track Grant (May 15, 2018): Aether received a $1.7 million Fast-Track Small Business Innovation Research Grant from the National Institute of Drug Abuse to develop preventive treatments for NAS.

• Licensing with OSU (July 1, 2018): Finalized a license with The Ohio State University for exclusive rights to use 6BN for NAS treatment.

• Collaboration with Ohio Neonatal Consortium (July 22, 2018): Partnered with Ohio's Neonatal Research Centers to enhance patient recruitment and resource utilization for NAS treatment studies.

Conferences and Presentations

• APS Meeting and World Pharma 2021: Wolfgang Sadee, Aether's CSO, was invited to present at these prestigious events, highlighting the company's research efforts.

Contact Information

• Email: info@aetherthx.com

For more information, please reach out to Aether Therapeutics at the provided contact email.